GleamWall
中文EN

OCS Oculis Holding AG IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1953530 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-15.4%
TTM EPS YoY10.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-73.5%
ROA-55.5%
ROIC (approx.)-80.4%
Asset turnover—

Leverage & solvency

Liabilities / assets16.9%
Debt / equity0.00x
Current ratio5.96x
Interest coverage-98.05x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-18.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF 2025Q2*2025-06-302024Q2*2024-06-302023Q2*2023-06-30
Income statement
Revenue———
R&D expense14.91M16.46M6.20M
SG&A expense6.12M6.26M4.80M
Operating income-20.77M-22.48M-10.74M
Interest expense183,00087,00017,000
Pretax income-25.40M-20.81M-12.76M
Income tax-24,00030,000114,000
Net income-25.38M-20.84M-12.88M
EPS (basic)-0.49-0.51-0.38
EPS (diluted)-0.49-0.51-0.38
Weighted avg. shares (diluted)52.29M40.54M33.57M
Balance sheet
Cash & equivalents64.27M43.85M41.93M
Current assets166.20M124.63M—
PP&E, netmay include right-of-use assets (IFRS)441,000249,000—
Intangibles13.29M12.21M—
Total assets181.62M138.73M—
Current liabilities36.55M23.63M—
Total liabilities38.52M25.91M—
Shareholders' equity143.10M112.83M117.20M
Cash flow statement
Operating cash flow———
Stock-based compensation—1.00M—

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.